An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients not Previously Treated for Metastatic Pancreatic Adenocarcinoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508356-19-00

Acronym

TTX-030-003

Enrollment

Registered

2024-05-27

Start date

2024-06-25

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic adenocarcinoma metastatic

Brief summary

Progression-free survival (PFS)

Detailed description

Progression-free survival, Objective response rate, Duration of response, Overall survival (PFS, ORR, DoR, OS), Type, severity, and frequency of treatment-emergent AEs

Interventions

DRUGBudigalimab

DRUGPACLITAXEL

DRUGTTX-030

DRUGGEMCITABINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS)	—

Secondary

Measure	Time frame
Progression-free survival, Objective response rate, Duration of response, Overall survival (PFS, ORR, DoR, OS), Type, severity, and frequency of treatment-emergent AEs	—

Countries

Czechia, France, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026